EMPOWER YOURSELF

What this means for you

This application is over — abandoned 21 Jul 2023. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.

Record

Serial number

88356940

Mark type

Stylized text

Filed

26 Mar 2019

Abandoned

21 Jul 2023

Attorney of record

Nicole K. McLaughlin

Goods and services

• Class 005 — Pharmaceuticals: Pharmaceutical preparations, namely, nonsteroidal anti-inflammatory drugs (NSAIDs), ibuprofen, naproxen sodium, acetaminophen, cold, sore throat and cough medications, guaifenesin, liquid cough medicines with dextromethorphan, decongestant nasal sprays, pseudoephedrine, phenylephrine, allergy medications, antihistamine pills and liquids, diphenhydramine, chlorpheniramine, brompheniramine, loratadine, fexofenadine, cetirizine, stomach upset medications, antidiarrhea medicines, loperamide, bismuth, nausea and vomiting, motion sickness, dimenhydrinate; cannabidiol (CBD) which is synthetically derived with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis for medical purposes; cannabidiol (CBD) which is synthetically derived with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis for treating, reducing or improving symptoms of various conditions, namely, pain, anxiety, depression, cancer, acne, skin conditions, neuroprotection, cardiovascular health, arthritis, inflammation, autoimmune conditions, epileptic seizures, nausea, appetite, inflammatory bowel disease, and insomnia; cannabidiol (CBD) which is synthetically derived with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis for medical purposes in sublingual doses and mucous membrane doses; skin creams, ointments, tablets, capsules, gummies, suppositories, skin patches, extended release tablets and liquids for therapeutic purposes containing cannabidiol (CBD) which is synthetically derived with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; herbal supplements containing cannabidiol (CBD) which is synthetically derived with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; Liquid nutritional supplements containing cannabidiol (CBD) which is synthetically derived with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis for treating, reducing or improving symptoms of various conditions, namely, pain, anxiety, depression, cancer, acne, skin conditions, neuroprotection, cardiovascular health, arthritis, inflammation, autoimmune conditions, epileptic seizures, nausea, appetite, inflammatory bowel disease, and insomnia

Owner

• EmpowerPharm Inc., Burlington, Ontario, CA

Prosecution history

• 04 Aug 2023 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
• 04 Aug 2023 — ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
• 04 Aug 2023 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
• 12 Apr 2023 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
• 12 Apr 2023 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
• 20 Jan 2023 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 20 Jan 2023 — NON-FINAL ACTION E-MAILED
• 20 Jan 2023 — NON-FINAL ACTION WRITTEN
• 22 Dec 2022 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 22 Dec 2022 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 20 Dec 2022 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
• 20 Dec 2022 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
• 20 Dec 2022 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
• 20 Dec 2022 — TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
• 28 Jul 2022 — NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED